公司概述
Crescent Biopharma, Inc. operates as a biotechnology enterprise focused on researching and developing cancer therapy candidates within the United States. The company functions within the Healthcare sector and the Biotechnology industry, positioning itself to leverage advancements in oncology treatments for solid tumors. Its operational scale is defined by a market capitalization of $581.53M, annual revenue of $10.84M over the trailing twelve months, and a workforce comprising 44 employees. These valuation and revenue figures indicate that the company holds a mid-tier market cap relative to its revenue generation, reflecting the high-risk, high-reward profile typical of early-stage biotechnology firms where significant capital is often required to advance clinical candidates like CR-001 through Phase 3 trials. The disparity between its substantial market cap and modest revenue underscores the market's pricing in of future pipeline potential rather than current profitability.
财务健康
The company reported a revenue of $10.84M for the trailing twelve months, yet it recorded a net income of -$153,942,000 and an EBITDA of -$152,548,000, revealing a cost structure where operational expenses significantly outweigh current income. This substantial gap between revenue and net income highlights the heavy investment in research and development necessary to progress its proprietary anti-PD-1/anti-VEGF bispecific antibody and other pipeline candidates. Free cash flow stands at -$153,697,632, indicating that the company is currently burning cash to fund its operations and clinical trials, which limits immediate financial flexibility but is common for development-stage biotechs. The gross margin is reported at 100.0%, suggesting that cost of goods sold is negligible compared to revenue, while the operating margin of -843.7% and profit margin of 0.0% reflect the aggressive spending required to sustain growth. In terms of liquidity, the company holds $213.19M in cash against only $1.64M in debt, resulting in a debt-to-equity ratio of 0.81, which suggests a balance sheet that is leveraged primarily through equity dilution potential rather than significant interest-bearing obligations. The current ratio of 6.56 indicates a strong short-term liquidity position, providing ample coverage for current liabilities. Furthermore, the return on equity is -160.7% and the return on assets is -69.1%, metrics that reveal that management is currently utilizing shareholder capital to generate losses, a typical characteristic of companies in the expansion phase of the product lifecycle.
估值评估
The trailing twelve-month P/E ratio is N/A due to negative earnings, while the forward P/E is listed at -5.34, implying that the market expects earnings to remain negative or volatile in the near term. The price-to-book ratio stands at 3.19, indicating that the market is valuing the company at a significant premium over its book value, likely driven by the intrinsic value of its intellectual property and clinical pipeline assets. Alternative valuation metrics include a price-to-sales ratio of 53.63 and an EV/EBITDA of -2.80, which suggest that investors are pricing the stock based on future revenue potential and clinical success probabilities rather than current profitability. The stock's trading range over the last year spans from a 52-week low of $8.72 to a 52-week high of $29.00, placing the current valuation context within a wide band of historical volatility typical for biotech equities. The beta value is listed as N/A, meaning that standard volatility metrics relative to the broader market index are not currently quantifiable for this specific stock.
Growth & Income
The revenue growth year-over-year is N/A and earnings growth year-over-year is N/A, as the company has not yet achieved consistent positive earnings to calculate meaningful growth rates. Since the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%, confirming that all available earnings are theoretically available for reinvestment, though currently negative. Instead of distributing income to shareholders, the company reinvests its limited cash reserves and potentially new capital raises directly into advancing its clinical trials and expanding its research capabilities. The overall growth and income profile is characterized by zero current income distribution and a reliance on external financing or cash reserves to fuel the development of its cancer therapy candidates without generating positive earnings growth in the short term.